The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …

Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods …

Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …

Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …

Lung cancer is the leading cause of cancer-related death. The identification of epidermal
growth factor receptor (EGFR) somatic mutations defined a new, molecularly classified …

Summary MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung
cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET …